According to Data Bridge Market Research new Market report, global xerostomia therapeutics market will account to an estimated USD 648.94 billion in 2017 growing at a CAGR of 3.8% during the forecast period of 2019 to 2026. Access Full Report at https://databridgemarketresearch.com/reports/global-xerostomia-therapeutics-market
Global Xerostomia Therapeutics Market
Change in the composition of saliva or reduced saliva flow, can cause xerostomia which can cause dryness in the mouth. They are usually caused due to the shrinkage of salivary gland and are very common in aging population. Cracked lips, bad breath and sticky saliva are the symptoms of this dry mouth. The dry mouth symptoms impacts the life style quality of the patient and causes difficulty in the swallowing, chewing and speaking which can lead to the thick oral mucus, sleep disturbance and bad breathing. It is caused due to the side effects of the medicine like antihistamines, decongestants, hypertensive medications, antidiarrheal, muscle relaxants etc.
Segmentation: Global Xerostomia Therapeutics Market
Global xerostomia therapeutics market is segmented on the basis of type, prescription and geography. By Type (Salivary Stimulants, Salivary Substitutes, Dentifrices), Prescription based (OTC, Prescribed), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) FACTORS DRIVING GROWTH IN XEROSTOMIA THERAPEUTICS MARKET Increasing Geriatric Population It is expected that the world’s population aged 60 years will be 2 billion by 2050, which is 900 million in 2015. Japan has the 27% of the population of 65 years of age or older which is the highest in 2015-16. Then is Italy with 23% and then Portugal with 22%. Then other countries like Germany, Bulgaria and Finland with 21%, Greece, Sweden, Latvia and Croatia with 20% respectively.
Key Market Competitors: Global Xerostomia Therapeutics Market
Few of the major market competitors currently working in the xerostomia therapeutics market are Acacia Pharma Group PLC, Colgate-Palmolive, Church & Dwight Co. Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Lupin, OraCoat, Parnell Pharmaceuticals Inc., Pendopharm, Pfizer Inc., Sun Pharmaceutical Industries Ltd, and Synedgen Inc. Browse Related Reports: Global Prostate Cancer Therapeutics Market, By Drug Type (Hormonal Therapy, Luteinizing Hormone-Releasing Hormone (LHRH) Agonist, Anti-Androgens, Immunotherapy, Targeted Therapy, Chemotherapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast to 2025 https://databridgemarketresearch.com/reports/global-prostate-cancer-therapeutics-market Global Lung Cancer Therapeutics Market, By Disease Type (Non-small cell lung cancer (NSCLC), Small cell lung cancer (SCLC)), Type of Molecule (Small molecules, Biologics), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)– Industry Trends and Forecast to 2025 https://databridgemarketresearch.com/reports/global-lung-cancer-therapeutics-market Global Leukemia Therapeutics Market, By Disease Type (Chronic Lymphatic Leukemia, Acute Lymphatic Leukemia), By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Surgery), By Stages (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia), By Geography (North America, Europe, Asia-Pacific, Europe, South America, Middle East & Africa)– Industry Trends and Forecast to 2025 https://databridgemarketresearch.com/reports/global-leukemia-therapeutics-market